547 Reprogramming of type I interferon-responding tumor-reactive T lymphocytes associates with improved outcomes to neoadjuvant doublet immunotherapy in HNSCC

• Lazar Vujanovic,
• Riyue Bao,
• Uma Duvvuri,
• Seungwon Kim,
• Robert Ferris,
• Aditi Kulkarni,
• Patricia Santos,
• Dan P Zandberg,
• Simon Chiosea,
• Housaiyin Li,
• Brian Isett,
• Joy Marion,
• Mark Kubik

Affiliations

Lazar Vujanovic

1University of Pittsburgh, Pittsburgh, PA, USA

Riyue Bao

UPMC Hillman Cancer Center, Pittsburgh, Pennsylvania, USA

Uma Duvvuri

Aff522 grid.21925.3d0000000419369000University of Pittsburgh Pittsburgh PA USA

Seungwon Kim

Aff522 grid.21925.3d0000000419369000University of Pittsburgh Pittsburgh PA USA

Robert Ferris

2UPMC Hillman Cancer Center, Pittsburgh, PA, USA

Aditi Kulkarni

1University of Pittsburgh, Pittsburgh, PA, USA

Patricia Santos

2UPMC Hillman Cancer Center, Pittsburgh, PA, USA

Dan P Zandberg

UPMC Hillman Cancer Center, Pittsburgh, PA, USA

Simon Chiosea

2UPMC Hillman Cancer Center, Pittsburgh, PA, USA

Housaiyin Li

1University of Pittsburgh, Pittsburgh, PA, USA

Brian Isett

UPMC Hillman Cancer Center, Pittsburgh, Pennsylvania, USA

Joy Marion

2UPMC Hillman Cancer Center, Pittsburgh, PA, USA

Mark Kubik

2UPMC Hillman Cancer Center, Pittsburgh, PA, USA